Business briefs: Otsuka, GSK, California health exchanges

Share this article:

Japanese drugmaker Otsuka said today it will buy Astex Pharmaceuticals for $886 million. Astex reported positive Phase II mid-stage results last month for its bone cancer treatment. Currently, Astex has one approved drug, Dacogen, which treats myelodysplastic syndromes—a blood disorder.

A melanoma vaccine from British drugmaker GSK fell short in late-stage trials. The treatment, MAGE-A3, did not extend disease-free survival compared to placebo—failing to meet its primary endpoint.

Health exchange consumers in California will be able to compare prices online, the Los Angeles Times reported. An online tool lets consumers see price information for all plans sold in their area.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.